🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. ARQ-151 cream 0.05%

    Arcutis Biotherapeutics

    Atopic Dermatitis (Eczema)

    phase 2 small molecule completed

    1 trial

  2. ARQ-154

    Arcutis Biotherapeutics

    Seborrheic Dermatitis

    phase 2 small molecule completed

    1 trial

  3. ARTEGENE

    Pari Pharma GmbH

    Severe Combined Immuno-Deficiency (SCID) caused by biallelic mutations in the Artemis gene (DCLRE1C)

    phase 2 small molecule active

    1 trial

  4. ASC30 tablets

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T2DM (Type 2 Diabetes Mellitus)

    phase 2 small molecule active

    1 trial

  5. ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib

    Novartis Pharmaceuticals

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  6. ASCT+CD7-CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CD7 Positive

    phase 2 small molecule active

    1 trial

  7. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. ASP8951, PACLITAXEL, GEMCITABINE

    Astellas Pharma GmbH

    First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

    phase 2 small molecule active

    1 trial

  9. AT-752

    Atea Pharmaceuticals

    Dengue Fever

    phase 2 small molecule terminated

    1 trial

  10. ATA188

    Evidence Based Cataract Study Group

    Primary Progressive Multiple Sclerosis

    phase 2 mab terminated

    1 trial

  11. ATI-045

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial

  12. ATI-045, Placebo to ATI-045

    Aclaris Therapeutics

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  13. ATI-1777

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  14. ATI-1777 2.0% w/w

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  15. ATI-2138

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  16. ATI-450

    Aclaris Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  17. ATI-502

    Aclaris Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  18. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  19. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  20. AUY922

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastrointestinal Stromal Tumor

    phase 2 small molecule active

    1 trial

  21. AV-101

    Vistagen Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  22. AVTX-009 Regimen 1

    Avalo Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  23. AVTX-801

    Ultragenyx UK Limited

    SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

    phase 2 small molecule active

    1 trial

  24. AXS-05

    Axsome Therapeutics

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources